The goal of this clinical trial is to learn if Ferric Carboxymaltose is a safe efficacious alternative to Iron Sucrose for treatment of Iron deficiency anemia in non-dialysis dependent chronic kidney disease patients. The main questions it aims to answer are:
* Does Ferric Carboxymaltose causes similar or higher rise in hemoglobin concentration and serum Ferritin and transferrin saturation
* What medical problems will participants have when receiving Ferric Carboxymaltose
Participants will:
* Be administered either Ferric Carboxymaltose or Iron Sucrose
* Visit the clinic at day 28 and 56 for checkup and tests
* Be monitored for any medical problem during and after infusion

Start Date02 Jun 2025

Sponsor / Collaborator

Sindh Institute of Urology & Transplantation

NCT06968936

/ RecruitingNot ApplicableIIT

Short-term Preoperative Combined Iron, Erythropoietin, and Vitamin C Therapy in Patients With Iron-deficiency Anaemia Undergoing Elective Cardiac Surgery: a Randomised Controlled Trial

The goal of this clinical trial is to learn if a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery. The trial will also look at whether this regimen is safe and well tolerated. The main questions it aims to answer are:
Does the combined regimen lower the amount of allogeneic red blood cell transfusion needed during and after surgery?
Are there any side effects or safety concerns associated with the regimen?
Researchers will compare the combined iron supplementation (sucrose iron, erythropoietin, and vitamin C) to standard care to see if it helps reduce blood transfusions.
Participants will:
Receive either the combined regimen or standard care before surgery
Undergo major elective cardiac surgery under general anesthesia
Be monitored for blood transfusion needs and recovery up to 90 days after surgery

Start Date15 May 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

[+5]

ChiCTR2400092079

/ SuspendedPhase 4IIT

A Study on the Use of Sucrose Iron and Carboxy Iron in the Perioperative Period of Hip Fracture in the Elderly of Southwest Sichuan Province

Start Date01 Jan 2025

Sponsor / Collaborator-

100 Clinical Results associated with Iron sucrose

100 Translational Medicine associated with Iron sucrose

100 Patents (Medical) associated with Iron sucrose

23,333

Literatures (Medical) associated with Iron sucrose

01 Oct 2025·APPLIED CATALYSIS B-ENVIRONMENTAL

Synergistic coupling of Ni-oxalate prism and layered FeOOH for oxygen evolution reaction in anion exchange membrane water electrolysis

Author: Long, Haowei ; Cho, Kangwoo ; Kwon, Soonho ; Kenis, Paul J. A. ; Goddard, William A. III ; Kim, Jiseon ; Ham, Kahyun ; Hong, Sukhwa

Hydrogen production in anion exchange membrane water electrolyzers (AEMWE) is significantly hindered by the challenges associated with the oxygen evolution reaction (OER).This anodic half-reaction requires a high overpotential and relies on costly precious metal-based electrocatalysts.This study introduces a novel OER electrocatalyst, layered FeOOH anchored on three-dimensional Ni oxalate prisms (FeOOH@NOP), synthesized via straightforward chem. bath deposition and electrodeposition methods.The FeOOH@NOP exhibits superior OER performance with a low overpotential of 336 mV at 100 mA cm^-2, along with remarkable operational durability over 100 h without any noticeable degradation in electrochem. activity.We investigated the adsorption site of OER intermediates on FeOOH@NOP utilizing in-situ X-ray absorption near edge structure and d. functional theory calculationsWe found that coupling NOP and FeOOH synergistically maintains the structural integrity, while the NOP inner layer enhances the OER activity on the FeOOH (the primary active sites) by stabilizing terminal oxo intermediates.The FeOOH@NOP achieved the superior hydrogen production rates in AEMWE with remarkable c.d. of 3.4 A cm^-2 at V_cell of 2.01 V, even compared to the benchmark Ir black and recently reported MOF-based anode materials.These results underscore its promising scalability and practical applicability for hydrogen generation.

01 Oct 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Surface reconstruction in LaOOH/Fe3O4 heterostructure for boosting alkaline oxygen evolution reaction at high current density

Author: Yu, Jie ; Zhang, Houjun ; Zhou, Qihang ; Wu, Jiangjiexing ; Zhang, Jinli ; Fu, Yan

Alk. water electrolysis (AWE) production still faces up with the challenge how to enhance the operational efficiency and lower the cell voltage under industrial c.d.With the purpose of exploring efficient catalyst with extremely low overpotential at high c.d. (500 mA.cm^-2) for oxygen evolution reaction (OER) in AWE, in this work, LaOOH/Fe₃O₄/NF catalysts were synthesized via in situ growth of LaOOH/Fe₃O₄ heterostructure on NF using a cyclic electrodeposition method with different La³⁺/Fe³⁺ ratios, and evaluated the electrochem. performance for OER, so as to accomplish the doping of rare earth element as well as modulation of desirable valence state of Fe species.The optimal catalyst LaOOH/Fe₃O₄-0.1/NF offered the overpotential of 350 mV at 500 mA.cm^-2 for OER, and maintained excellent stability in 100 h.Characterizations disclosed the rough and porous surface of LaOOH/Fe₃O₄-0.1/NF, resulting in its exceptional hydrophilicity and aerophobicity properties, as confirmed by the bubble formation and detachment behavior monitored using the high-speed camera and particle image velocimetry system.Combining with D. functional theory (DFT) calculations, it is illustrated that the extremely low overpotential at high c.d. over such catalyst for OER is due to the reconstructed La(OH)₃/FeOOH/Fe₃O₄/NF heterostructure, which can efficiently modulate the electronic structure and enhance the conductivity of the electrode.This work provides a facile route to explore novel electrochem. catalysts with multiple-element doping as well as desirable valence state of active species, but also shows a promising prospect to improve the operational efficiency of AWE industrial production

01 Oct 2025·SEPARATION AND PURIFICATION TECHNOLOGY

Adsorption, epimerization and self-sustaining degradation: Muti-step detoxification of tetracycline via chitosan-supported mixed-phase FeOOH

Author: Kai, Yin ; Du, Miaojia ; Shen, Chensi ; Wen, Yuezhong ; Ma, Jianqing ; Wu, Wenliang ; Zhao, Feng

Tetracycline (TC) antibiotics are common trace pollutants in aquatic environments, where they can accumulate and transform into epimers such as 4-epi-tetracycline (ETC), potentially increasing ecotoxicity.Therefore, developing effective and safe in-situ remediation technologies for the removal of TCs from natural waters is of critical importance.This study presents a fabrication method for magnetic chitosan-supported mixed-phase FeOOH particles (α/δ-FeOOH@CS), which are enriched with oxygen vacancies, for the adsorption and degradation of TCs.Significant epimerization of TC into ETC was observed during its removal.Batch experiments showed that 96% of TC and 97.6% of ETC could be removed by α/δ-FeOOH@CS.The main mechanism involves the chitosan-induced accumulation, Fe(III)-mediated complexation and oxidation, coupled with reactive oxygen species (ROS) generation initiated by Fe(II).These processes establish a self-sustaining Fe(III)/Fe(II) redox cycle for efficient in-situ remediation of TCs.The differing removal behaviors of TC and ETC are likely attributed to their distinct interactions with Fe(III), resulting from spatial changes in the C4 dimethylamino group.Addnl., algal toxicity tests conducted throughout the degradation process confirmed the near non-toxic nature of the removal steps, indicating that no significant new environmental toxic effects were introduced.

News (Medical) associated with Iron sucrose

10 Jun 2025

·www.prnewswire.com

Renibus Therapeutics Announces FDA Orphan Drug Designation for Veverimer for the Treatment of Anti-glomerular Basement Membrane Disease (anti-GBM)

SOUTHLAKE, Texas, June 10, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute renal failure associated with the presence of auto-immune antibodies with affinity for the glomerular basement membrane. "Ultra-rare life-threatening conditions, including anti-GBM and several other forms of glomerular and tubulointerstitial kidney diseases, can be aggressive and challenging to treat effectively with current therapies," said Bhupinder Singh M.D., Chief Medical Officer of Renibus. "This Orphan Drug Designation further underscores the potential of veverimer to offer a significant advantage beyond drugs currently used to treat kidney disease, and we look forward to advancing this asset in the clinic." The Orphan Drug Designation program is intended to encourage the development of products for diseases that affect fewer than 200,000 individuals in the United States. With this designation Renibus is eligible for certain incentives, such as tax credits for clinical trials, exemption from user fees, and a potential 7 years of market exclusivity upon approval. Richard Zager, Senior Vice President of Translational Research of Renibus, commented, "Veverimer markedly suppresses ammoniagenisis and associated activation of the complement cascade, which are key mediators of anti-GBM disease and other complement mediated renal diseases. We are continuing to evaluate the potential of veverimer to address these diseases of high unmet medical need." About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' lead first-in class combination drug therapy is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. RBT-1 has just completed enrollment in a Phase 3 pivotal trial (called PROTECT) measuring its primary objective to reduce the risk of post operative complications and improve outcomes following cardiac surgery. The drug has been granted FDA Breakthrough and Fast Track Designations by the Division of Cardiology and Nephrology at the FDA. Veverimer is an oral, non-absorbed hydrochloric acid binder that has been granted Orphan Drug Designation for the treatment of anti-glomerular basement membrane disease. Renibus is also evaluating veverimer's potential use for the treatment of other renal diseases. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Orphan DrugFast TrackPhase 3

25 Apr 2025

·www.prnewswire.com

Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA)

- Renibus recently completed enrollment in a Phase 3 pivotal trial PROTECT to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - SOUTHLAKE, Texas, April 25, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced that a poster presentation will be delivered on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA), taking place April 26-29, 2025 in Montreal. RBT-1 is a single-dose, first-in-class, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing non-emergent cardiac and/or valve surgery. Renibus previously completed a Phase 2 study of RBT-1 (NCT04564833) in February 2023, announced positive final results from this study in May 2023, and has recently completed enrollment in its Phase 3 PROTECT study. RBT-1 has received Breakthrough and Fast Track Designations from the US FDA. "We are excited to build on our recent momentum of achieving full enrollment in our Phase 3 PROTECT study with a poster presentation at SCA 2025 that we can share with the global anesthesiologist community," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "Our poster highlights the complicated economic impact of post-operative complications and increasing costs for CABG and value surgery to the healthcare system, which directly affects anesthesiologists. With the use of RBT-1 in our Phase 2 study, we reduced the complication rates from cardiovascular surgery, and in turn, the overall healthcare costs. We look forward to continuing to demonstrate these encouraging results in Phase 3." Frans van Wagenberg, MD, Huntsville Heart Center, Huntsville, Alabama, commented, "I am pleased to present results of a cost-analysis based on a Phase 2 trial which suggest that RBT-1 has a protective effect, leading to lower complication rates and reduced average expected costs overall. Additional data from an ongoing Phase 3 trial, which includes a 1-year post-discharge follow-up, will further evaluate the impact of RBT-1 on clinical, economic, and qualitative outcomes compared to standard care." Details of the poster presentation at SCA 2025: Title: "Clinical and Economic Impact of RBT-1 on Post-operative Complications and Costs for CABG and Valve Surgery" Date and Time: Sunday, April 27, 2025 at 12:30 Authors: Frans van Wagenberg, MD, Lynn Cherry, PhD, Bhupinder Singh, MD, Stacey Ruiz, PhDc, Raf Magar MB About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory andantioxidant pathways currently being evaluated in the Phase 3 PROTECT study for its lead indication to reduce post-operative complications following cardiothoracic surgery. Previously, Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study and announced completion of enrollment in April 2025. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial (called PROTECT) to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. The drug has received FDA Orphan Drug Designation. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Fast TrackPhase 2Orphan DrugBreakthrough Therapy

26 Mar 2025

·www.prnewswire.com

Renibus to Participate in the 24th Annual Needham Healthcare Virtual Healthcare Conference

SOUTHLAKE, Texas, March 26, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced its participation in the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. This event is being held in a virtual format during which Company management will participate in one-on-one meetings with investors. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Fast Track

100 Deals associated with Iron sucrose

External Link

KEGG	Wiki	ATC	Drug Bank
D04616	Iron sucrose	B03AB02	DB09146

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Kidney Failure, Chronic	Canada	Vifor Fresenius Medical Care Renal Pharma Ltd.	05 Jan 2018
Hyperphosphatemia	Japan	Kissei Pharmaceutical Co., Ltd.	28 Sep 2015
Iron deficiency	Australia	Seqirus Pty Ltd.	19 May 2004
Chronic Kidney Diseases	United States	American Regent, Inc.	06 Nov 2000
Anemia, Iron-Deficiency	Switzerland	Corden Pharma Fribourg SA	02 Jun 1949

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 3	-	American Regent, Inc.	01 Feb 2003
Anemia	Phase 3	-	American Regent, Inc.	01 Jul 2002
Kidney Diseases	Phase 2	Austria	Vifor Fresenius Medical Care Renal Pharma Ltd.	09 Jun 2017
Inflammatory Bowel Diseases	Phase 2	United States	American Regent, Inc.	01 Nov 2011
Proteinuria	Phase 1	United States	Actavis, Inc.	01 Sep 2007
Proteinuria	Phase 1	Puerto Rico	Actavis, Inc.	01 Sep 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04485039 (CTgov)	Phase 4	Smallpox	44	Tecovirimat (TPOXX: Oral Antiviral)	ubgspolgwj(ansbnxqxhy) = ojdbutjctt xlhgagvmrl (llzdkupedq, 39.6) View more	-	09 Oct 2024
				Tecovirimat+sevelamer carbonate oral tablet (TPOXX: Oral Antiviral and Sevelamer Carbonate)	onfhxopahq(skhwpfayzb) = witkwtzvyy yjmkpuqere (egxpsutjuu, nfheviruln - yvhlavbxcx) View more
SOHO2024	Not Applicable	Hypophosphatemia	-	Ferric hydroxide-sucrose	cddbvykatm(wmclgrbutz) = girgdwviqe kqkfqyrhzj (znphtecweu )	-	04 Sep 2024
SOHO2023	Not Applicable	-	-	Ferric Carboxymaltose (FCM)	rgowraoowx(ruwpebvsmj): risk ratio = 0.97 (95% CI, 0.62 - 1.51), P-Value = 0.86 View more	-	01 Sep 2023
				Iron Sucrose (IS)
NCT03644264 (Pubmed)	Phase 3	Hyperphosphatemia	286	Sucroferric oxyhydroxide	xetpstggjg(ycshfnoqap) = gypapeluxu oatuqfjlta (yzsmupgdad )	Positive	20 Jul 2023
				Sevelamer carbonate	xetpstggjg(ycshfnoqap) = dzxfrauaid oatuqfjlta (yzsmupgdad )
NCT03644264 (WCN23-0681, ISN WCN2023)	Phase 3	Hyperphosphatemia	415	Sucroferric oxyhydroxide (SFOH)	hendwtdwnt(cptccfhqho) = uwczffphkp epkjubbeea (zwwxtgbolh, 0.60) View more	Positive	01 Mar 2023
				Sevelamer carbonate	hendwtdwnt(cptccfhqho) = lonolfyhtq epkjubbeea (zwwxtgbolh, 0.52) View more
DaVita Biorepository (ASN2022)	Not Applicable	iron sucrose	950	Iron Sucrose administration	lfmmigspqc(txirppecav) = rltjavsxvu idtgpergep (xzpeqevkcd )	Positive	05 Nov 2022
				No Iron Sucrose administration	-
ASN2022	Not Applicable	sP \| sCa \| iPTH	100	Sucroferric oxyhydroxide	wtkcxkiaxj(cucsrdendj) = jahweqxxmg aivzalvxsp (qthldpqvzk )	Positive	03 Nov 2022
NCT04046263 (CTgov)	Phase 4	Hyperphosphatemia \| Peritoneal dialysis complication \| Hypoalbuminemia	17	Sucroferric Oxyhydroxide Chewable Tablet	qvnklgyeyx(wzedzbqqof) = ubrndjmpon nsigqkrwzm (llnkdbucyb, 1.76) View more	-	31 Aug 2022
ERA2022	Not Applicable	Chronic Kidney Diseases skeletal plasma clearance of tracer (K i ) \| bone volume/tissue volume (BV/TV)	-	Sucroferric oxyhydroxide	nbqkeluqyh(eanneeglhq) = BV/TV (volume) was significantly lower after SO treatment than after CC treatment ntpswayqgk (ppwzfypfmt )	-	03 May 2022
				Calcium carbonate
ERA2022	Not Applicable	Bone Diseases FGF23 \| soluble Klotho \| c-reactive protein (CRP) ... View more	50	Sucroferric oxyhydroxide	jxgnfcxrut(jadvgsuqnj) = nkghlaqrox vyjrguyajp (yjgacqcgnz ) View more	Positive	03 May 2022
				Sevelamer	sijanfrezl(ybhwwuplts) = nepmmsddeu rjetcscjte (pxvgjiofil )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Iron sucrose

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation